Similarly, the KEYNOTE-811 [8] trial has demonstrated the efficacy of combining trastuzumab and pembrolizumab as the 1st-line treatment for HER2-positive gastric cancer, marking a notable advancement. This evidence concerns the gene ERBB2 and gastric cancer.